View All Documents & Correspondence
Combination Probiotic Compositions
Abstract: Combinations of probiotic compositions are described which are beneficial for human hosts in reducing gas and bloating, stomach acidity, and constipation also capable of boosting the immune capacity. The compositions comprise blends including B. coagulans, B. subtilis, and B. clausii in combination with magnesium stearate, magnesium hydroxide, and simethicone. The combination probiotic compositions of the present invention behave in a synergistic manner in their nature of action both in-vitro and in-vivo. The combination probiotic compositions of the present invention are also very stable for comparatively greater amounts of time period.
Notices, Deadlines & Correspondence
Patent Information
Applicants
SANZYME BIOLOGICS PRIVATE LIMITED
Inventors
1. SOMAN RAUNAK JAY
2. MALISETTY VENKAT SWAMY
Specification
DESC:Pl find as attached and uploaded. ,CLAIMS:1. A probiotic blend composition comprising B. coagulans, B. subtilis, and B. clausii in combination with magnesium stearate, magnesium hydroxide, and simethicone.
2. The probiotic blend composition of claim 1, wherein the probiotic blend composition contains a total dosage of about 2 Billion CFUs.
3. The probiotic blend composition of claim 1, wherein the amount of B. coagulans is between about 0.5 Billion to about 1.5 Billion CFUs, the amount of B. clausii between about 0.1 Billion to about 0.5 Billion CFUs, and the amount of B.subtilis is between about 0.1 Billion to about 1.5 Billion CFUs.
4. The probiotic blend composition of claim 1, wherein the amount of B. coagulans is about 1.4 Billion CFUs, the amount of B. subtilis is about 0.1 Billion CFUs, and the amount of B. clausii is about 0.5 Billion CFUs.
5. The probiotic blend of claim 1, wherein B. coagulans is SNZ 1969, B. subtilis is SNZ 1972 and B. clausii is SNZ 1971.
6. A method for improving digestion of complex carbohydrates, proteins and fibers , comprising the steps of:
providing a probiotic blend composition comprising B. coagulans, B. subtilis, and B. clausii in combination with magnesium stearate, magnesium hydroxide, and simethicone;
administering to the human the probiotic blend composition.
7. The method of claim 8, wherein the probiotic blend composition contains a total dosage of about 2 Billion CFUs.
8. The method of claim 8, wherein the amount of B. coagulans is between about 0.5 Billion to about 1.5 Billion CFUs, the amount of B. clausii between about 0.1 Billion to about 0.5 Billion CFUs, and the amount of B.subtilis is between about 0.1 Billion to about 1.5 Billion CFUs.
9. The method of claim 8, wherein the amount of B. coagulans is about 1.4 Billion CFUs, the amount of B. clausii is about 0.5 Billion CFUs, and the amount of B. subtilis is about 0.1 Billion CFUs.
10. The method of claim 8, wherein B. coagulans is SNZ 1969, B. subtilis is SNZ 1972, and . B. subtilis is SNZ 1971.
11. A method for increase in the probiotic population in the digestive system, comprising the steps of:
providing a probiotic blend composition comprising B. coagulans, B. subtilis, and B. clausii in combination with magnesium stearate, magnesium hydroxide, and simethicone;
administering to the human the probiotic blend composition.
12. The method of claim 11, wherein the probiotic blend composition contains a total dosage of about 2 Billion CFUs.
13. The method of claim 11, wherein the amount of B. coagulans is between about 0.5 Billion to about 1.5 Billion CFUs, the amount of B. clausii between about 0.1 Billion to about 0.5 Billion CFUs, and the amount of B.subtilis is between about 0.1 Billion to about 1.5 Billion CFUs.
14. The method of claim 11, wherein the amount of B. coagulans is about 1.4 Billion CFUs, the amount of B. clausii is about 0.5 Billion CFUs, and the amount of B. subtilis is about 0.1 Billion CFUs.
15. The method of claim 11, wherein B. coagulans is SNZ 1969, B. subtilis is SNZ 1972, and . B. subtilis is SNZ 1971.
16. A method for treating or preventing a condition in a human selected from the group consisting of irritable bowel syndrome (IBS), diarrhoea, bloating, formation of abdominal gas, constipation, bowel irregularity, and reactions to antibiotic treatment, comprising the steps of:
providing a probiotic blend composition comprising B. coagulans, B. subtilis, and B. clausii in combination with magnesium stearate, magnesium hydroxide, and simethicone; and
administering to the human the probiotic blend composition.
17. The method of claim 16, wherein the probiotic blend composition contains a total dosage of about 2 Billion CFUs.
18. The method of claim 16, wherein the amount of B. coagulans is between about 0.5 Billion to about 1.5 Billion CFUs, the amount of B. clausii between about 0.1 Billion to about 0.5 Billion CFUs, and the amount of B.subtilis is between about 0.1 Billion to about 1.5 Billion CFUs.
19. The method of claim 16, wherein the amount of B. coagulans is about 1.4 Billion CFUs, the amount of B. clausii is about 0.5 Billion CFUs, and the amount of B. subtilis is about 0.1 Billion CFUs.
20. The method of claim 16, wherein B. coagulans is SNZ 1969, B. subtilis is SNZ 1972, and B. subtilis is SNZ 1971.
21. The probiotic blend composition of claim 1 comprising B. coagulans SNZ1969 , B. subtilis SNZ1972, and B. clausii SNZ1971.
Documents
Application Documents
| # | Name | Date |
|---|---|---|
| 1 | 201841032444-NBA INTIMATION TO APPLICANT COMPLY WITH REQUIREMENT-05-01-2023.pdf | 2023-01-05 |
| 1 | 201841032444-PROVISIONAL SPECIFICATION [30-08-2018(online)].pdf | 2018-08-30 |
| 2 | 201841032444-Written submissions and relevant documents [30-03-2022(online)].pdf | 2022-03-30 |
| 2 | 201841032444-POWER OF AUTHORITY [30-08-2018(online)].pdf | 2018-08-30 |
| 3 | 201841032444-FORM 1 [30-08-2018(online)].pdf | 2018-08-30 |
| 3 | 201841032444-US(14)-HearingNotice-(HearingDate-16-03-2022).pdf | 2022-02-22 |
| 4 | 201841032444-DRAWINGS [30-08-2018(online)].pdf | 2018-08-30 |
| 4 | 201841032444-ABSTRACT [05-02-2022(online)].pdf | 2022-02-05 |
| 5 | 201841032444-PostDating-(30-08-2019)-(E-6-237-2019-CHE).pdf | 2019-08-30 |
| 5 | 201841032444-CLAIMS [05-02-2022(online)].pdf | 2022-02-05 |
| 6 | 201841032444-FER_SER_REPLY [05-02-2022(online)].pdf | 2022-02-05 |
| 6 | 201841032444-APPLICATIONFORPOSTDATING [30-08-2019(online)].pdf | 2019-08-30 |
| 7 | 201841032444-OTHERS [05-02-2022(online)].pdf | 2022-02-05 |
| 7 | 201841032444-FORM 3 [03-09-2019(online)].pdf | 2019-09-03 |
| 8 | 201841032444-ENDORSEMENT BY INVENTORS [03-09-2019(online)].pdf | 2019-09-03 |
| 8 | 201841032444-FER.pdf | 2021-10-17 |
| 9 | 201841032444-DRAWING [03-09-2019(online)].pdf | 2019-09-03 |
| 9 | 201841032444-FORM 18A [05-06-2021(online)].pdf | 2021-06-05 |
| 10 | 201841032444-COMPLETE SPECIFICATION [03-09-2019(online)].pdf | 2019-09-03 |
| 10 | 201841032444-FORM28 [05-06-2021(online)].pdf | 2021-06-05 |
| 11 | 201841032444-Request Letter-Correspondence [13-09-2019(online)].pdf | 2019-09-13 |
| 12 | 201841032444-Power of Attorney [13-09-2019(online)].pdf | 2019-09-13 |
| 13 | 201841032444-Form 1 (Submitted on date of filing) [13-09-2019(online)].pdf | 2019-09-13 |
| 14 | 201841032444-CERTIFIED COPIES TRANSMISSION TO IB [13-09-2019(online)].pdf | 2019-09-13 |
| 15 | 201841032444-MSME CERTIFICATE [05-06-2021(online)].pdf | 2021-06-05 |
| 16 | 201841032444-FORM28 [05-06-2021(online)].pdf | 2021-06-05 |
| 17 | 201841032444-FORM 18A [05-06-2021(online)].pdf | 2021-06-05 |
| 18 | 201841032444-FER.pdf | 2021-10-17 |
| 19 | 201841032444-OTHERS [05-02-2022(online)].pdf | 2022-02-05 |
| 20 | 201841032444-FER_SER_REPLY [05-02-2022(online)].pdf | 2022-02-05 |
| 21 | 201841032444-CLAIMS [05-02-2022(online)].pdf | 2022-02-05 |
| 22 | 201841032444-ABSTRACT [05-02-2022(online)].pdf | 2022-02-05 |
| 23 | 201841032444-US(14)-HearingNotice-(HearingDate-16-03-2022).pdf | 2022-02-22 |
| 24 | 201841032444-Written submissions and relevant documents [30-03-2022(online)].pdf | 2022-03-30 |
| 25 | 201841032444-NBA INTIMATION TO APPLICANT COMPLY WITH REQUIREMENT-05-01-2023.pdf | 2023-01-05 |
Search Strategy
| 1 | searchstrategyE_30-07-2021.pdf |